Close

Goldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Neutral

December 5, 2014 6:36 AM EST Send to a Friend
Goldman Sachs initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Neutral rating and a price target of $40.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login